Details of Disease

General Information of Disease (ID: DISNH7P9)

Disease Name	Colorectal cancer
Synonyms	colon cancer; colon cancer, susceptibility to, autosomal dominant, somatic mutation; large intestine cancer; CRC; malignant colorectum neoplasm; malignant large intestine neoplasm; malignant large intestine tumor; malignant tumour of the large intestine; malignant large bowel neoplasm; malignant tumor of the large bowel; malignant large intestine tumour; colon cancer, somatic; malignant tumor of large intestine; colon cancer, advanced, somatic; cancer of large intestine; cancer of large bowel; malignant neoplasm of the large bowel; colorectum cancer; colorectal cancer, autosomal dominant, somatic mutation; malignant large bowel tumor; malignant large bowel tumour; cancer of colorectum; malignant tumour of large intestine; malignant tumour of the large bowel; cancer of the large bowel; colorectal cancer with chromosomal instability, somatic; malignant neoplasm of the large intestine; malignant neoplasm of colorectum; colorectal cancer; colorectal cancer, somatic; colorectal cancer, susceptibility to, autosomal dominant, somatic mutation; malignant neoplasm of large bowel; malignant colorectal neoplasm; malignant tumor of large bowel; malignant tumour of large bowel; malignant colorectal tumor; malignant colorectal tumour; malignant neoplasm of large intestine; malignant tumor of the large intestine
Disease Class	2B91: Colorectal cancer
Definition	A primary or metastatic malignant neoplasm that affects the colon or rectum. Representative examples include carcinoma, lymphoma, and sarcoma.\|Editor note: some sources make distinct classes for colorectal vs large intestine. We follow NCIT and make these equivalent
Disease Hierarchy	DIS7RWHZ: Intestine cancer DISR1UCN: Colorectal neoplasm DISAT1Z9: Advanced cancer DISNH7P9: Colorectal cancer
ICD Code	ICD-11 ICD-11: 2B91.Z Expand ICD-9 153154
Disease Identifiers	MONDO ID MONDO_0005575 UMLS CUI C0346629 MedGen ID 83428 Orphanet ID 466667 SNOMED CT ID 363510005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 18 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[2]
Capecitabine	DMTS85L	Approved	Small molecular drug	[3]
Cetuximab	DMLNCE0	Approved	Antibody	[4]
Entrectinib	DMMPTLH	Approved	Small molecular drug	[5]
Floxuridine	DM04LR2	Approved	Small molecular drug	[6]
Fluorouracil	DMUM7HZ	Approved	Small molecular drug	[7]
Fruquintinib	DMHOSCQ	Approved	NA	[8]
Intedanib	DMSTA36	Approved	Small molecular drug	[9]
Irinotecan	DMP6SC2	Approved	Small molecular drug	[10]
mab17-1a	DMIX1MX	Approved	Monoclonal antibody	[11]
Midostaurin	DMI6E0R	Approved	Small molecular drug	[12]
Necitumumab	DMKOJSN	Approved	Monoclonal antibody	[13]
Oxaliplatin	DMQNWRD	Approved	Small molecular drug	[14]
Panitumumab	DMQPD1F	Approved	Monoclonal antibody	[15]
Pembrolizumab	DMFQEA6	Approved	Monoclonal antibody	[1]
Technetium TC 99M votumumab	DM8T8YT	Approved	Monoclonal antibody	[11]
Trastuzumab deruxtecan	DMRI010	Approved	Antibody drug conjugate	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 Drug(s)

This Disease is Treated as An Indication in 111 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
OncoVAX	DMMPRAX	Preregistration	NA	[16]
AP12009	DMUYOC8	Phase 3	Antisense drug	[17]
Arfolitixorin	DMIXMYK	Phase 3	Small molecular drug	[18]
DCVax	DMC5VJY	Phase 3	NA	[19]
EXISULIND	DMBY56U	Phase 3	Small molecular drug	[20]
GDC-0068	DMWBZJD	Phase 3	Small molecular drug	[1]
Hu5F9-G4	DMBER0Q	Phase 3	NA	[2]
INCB24360	DMIJGT9	Phase 3	Small molecular drug	[1]
JX-594	DM5WCV4	Phase 3	NA	[21]
MABp1	DM8D13S	Phase 3	NA	[1]
MGN-1703	DMCJRL1	Phase 3	NA	[22]
Napabucasin	DMDZ6Q3	Phase 3	NA	[1]
NGR-hTNF	DM3PZLM	Phase 3	NA	[23]
NKTR 214	DM376WT	Phase 3	NA	[2]
Pelareorep	DM4WCF9	Phase 3	NA	[2]
Picoplatin	DM0PIY6	Phase 3	Small molecular drug	[24]
Resveratrol	DM3RWXL	Phase 3	Small molecular drug	[25]
RIGS CC49	DMKPM5R	Phase 3	NA	[26]
SNDX-275	DMH7W9X	Phase 3	Small molecular drug	[1]
STI-001	DME0XSP	Phase 3	NA	[2]
SYM-004	DMOVEDH	Phase 3	Antibody	[2]
TAS-102	DMOJV2N	Phase 3	Small molecular drug	[27]
TRS003	DMM1VOH	Phase 3	Antibody	[28]
Xilonix	DMK34MZ	Phase 3	NA	[29]
Zarnestra	DMF30HL	Phase 3	Small molecular drug	[30]
Imprime PGG	DMIUA3M	Phase 2/3	NA	[1]
MelCancerVac	DMTIQXD	Phase 2/3	NA	[31]
Abituzumab	DMTCXSG	Phase 2	Antibody	[32]
Ad-p53	DMJSWXL	Phase 2	NA	[33]
BNT122	DMD0FNY	Phase 2	Vaccine	[34]
CeaVac	DM6Z9BV	Phase 2	Vaccine	[35]
Conatumumab	DM2UOSN	Phase 2	Monoclonal antibody	[36]
DN24-02	DM725UG	Phase 2	NA	[37]
E7820	DMZRXTL	Phase 2	Small molecular drug	[38]
EFT508	DMX6RZG	Phase 2	NA	[1]
GI-4000	DMTY4PG	Phase 2	Vaccine	[39]
GS-6624	DMV7ZU0	Phase 2	Antibody	[40]
GSK2141795	DMSHE70	Phase 2	Small molecular drug	[41]
IDM-2101	DMABRXY	Phase 2	Vaccine	[42]
IL-21	DM1E4VP	Phase 2	NA	[43]
L19-TNF-alpha	DMW6NMP	Phase 2	Antibody	[44]
Labetuzumab govitecan	DMW9F89	Phase 2	NA	[2]
Labetuzumab I-131	DMNO5UE	Phase 2	Antibody	[45]
LE-SN38	DMW50NF	Phase 2	Small molecular drug	[46]
MEHD-7945A	DMHOF7T	Phase 2	NA	[47]
MORAb-004	DMGK1JE	Phase 2	NA	[48]
MSC1936369B	DMH1DYU	Phase 2	Small molecular drug	[49]
MUC1-Poly-ICLC	DML7N4B	Phase 2	Vaccine	[50]
Novaferon	DMEHOI1	Phase 2	NA	[51]
NPC-1C	DM9VEAL	Phase 2	Antibody	[52]
Ontuxizumab	DM0FJIE	Phase 2	Antibody	[53]
PM184	DMS34YO	Phase 2	NA	[1]
PYRAZOLOACRIDINE	DMSOPAU	Phase 2	Small molecular drug	[54]
RG7221	DM8J9DC	Phase 2	NA	[55]
RNF43-721	DM20CIM	Phase 2	NA	[56]
RO5520985	DMD3WNP	Phase 2	Monoclonal antibody	[57]
SDZ-SCV-106	DM7KBHV	Phase 2	NA	[58]
Seribantumab	DMYT470	Phase 2	NA	[2]
Simtuzumab	DM5SFWW	Phase 2	Monoclonal antibody	[59]
Tigatuzumab	DMKYJJC	Phase 2	Monoclonal antibody	[60]
U3-1402	DMLPFPE	Phase 2	NA	[61]
UFT/leucovorin calcium	DMWDJ15	Phase 2	NA	[62]
Varlilumab	DMQSC5O	Phase 2	NA	[1]
XR-5000	DMOKUA5	Phase 2	NA	[63]
Anti-C-met CAR-T cells	DMV5H0S	Phase 1/2	CAR T Cell Therapy	[64]
Anti-HER2 CAR-T	DMQD6B9	Phase 1/2	CAR T Cell Therapy	[65]
Anti-MUC1 CAR-T cells	DMTQIB2	Phase 1/2	CAR T Cell Therapy	[66]
ATP128	DMV0VXE	Phase 1/2	Vaccine	[67]
AVX701	DMOPVIQ	Phase 1/2	NA	[68]
CAR-T cells targeting CEA	DM6VCPX	Phase 1/2	CAR T Cell Therapy	[69]
EGFR CART	DMDWCOF	Phase 1/2	CAR T Cell Therapy	[70]
Eltanexor oral	DM7CLEZ	Phase 1/2	NA	[1]
ETBX-011 cancer vaccine	DMQFDMH	Phase 1/2	NA	[16]
IMA-910	DMUYBRY	Phase 1/2	NA	[71]
ISA-P53-01	DMQ5EYJ	Phase 1/2	Vaccine	[72]
KRN-330	DMA5B1S	Phase 1/2	Antibody	[73]
MGD007	DMAHWLR	Phase 1/2	Monoclonal antibody	[74]
NKTR-255	DM7SMNJ	Phase 1/2	NA	[75]
ONCOS-102	DMACFVN	Phase 1/2	Oncolytic virus therapy	[1]
Onyvax-105	DMGIN7J	Phase 1/2	Vaccine	[76]
OTSGC-A24	DMN0ZQ5	Phase 1/2	Vaccine	[77]
PA-799	DMLSYJQ	Phase 1/2	Small molecular drug	[78]
PolyPEPI1018	DMYUYCA	Phase 1/2	Vaccine	[79]
AbGn-107	DMRZMPB	Phase 1	NA	[1]
ADXS-NEO	DMFJ1OW	Phase 1	Vaccine	[80]
Aimpila	DMR98Z9	Phase 1	NA	[81]
AMP-224	DMH9M62	Phase 1	Monoclonal antibody	[82]
Anti-CD133-CAR vector-transduced T cells	DMGUM90	Phase 1	CAR T Cell Therapy	[83]
Anti-CEA CAR-T cells	DMA7L3O	Phase 1	CAR T Cell Therapy	[84]
Anti-CEA-CAR T	DMJA3H1	Phase 1	CAR T Cell Therapy	[85]
Brontictuzumab	DMDKYQQ	Phase 1	NA	[2]
CIGB-M3	DMSGRA7	Phase 1	Antibody	[86]
CX-904	DMOOHDN	Phase 1	Bispecific T-cell engager	[87]
CYAD-101	DMSM42V	Phase 1	CAR T Cell Therapy	[88]
Cyclolignan picropodophyllin	DMI6EUB	Phase 1	NA	[89]
DS-8273	DMJPUDW	Phase 1	Antibody	[2]
Entolimod	DMMJXAR	Phase 1	NA	[1]
FluCell	DMZW4C3	Phase 1	NA	[90]
HuA33	DMB3LQU	Phase 1	Antibody	[91]
JNJ-64251330	DMWD8WG	Phase 1	Small molecule	[92]
MVT-5873	DMEJ4C1	Phase 1	NA	[2]
Navicixizumab	DMZ2G69	Phase 1	NA	[2]
NBF-006	DMG0SWE	Phase 1	Small interfering RNA	[93]
PLADD	DM636KE	Phase 1	NA	[16]
Radiolabelled-huA33	DMIEJ0W	Phase 1	Antibody	[94]
RG6286	DMVFHQP	Phase 1	NA	[95]
Rosmantuzumab	DM9O3RY	Phase 1	NA	[2]
SART3 peptide cancer vaccine	DMX9VWT	Phase 1	NA	[96]
SC-006	DMZ4NHG	Phase 1	NA	[1]
Tetrandrine	DMAOJBX	Phase 1	Small molecular drug	[97]
TF2	DMEHYO6	Phase 1	Small molecular drug	[98]
------------------------------------------------------------------------------------


⏷ Show the Full List of 111 Drug(s)

This Disease is Treated as An Indication in 1 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID28460551-Compound-1	DMHV75N	Patented	Small molecular drug	[99]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 15 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atiratecan	DMZEMG6	Discontinued in Phase 2	Small molecular drug	[100]
GL-331	DM10CBF	Discontinued in Phase 2	Small molecular drug	[101]
IGN-101	DMOG1LX	Discontinued in Phase 2	Vaccine	[102]
RG7414	DMCQRS2	Discontinued in Phase 2	NA	[103]
RNAPc2	DME9V0I	Discontinued in Phase 2	NA	[104]
Robatumumab	DMOEQO1	Discontinued in Phase 2	Monoclonal antibody	[105]
KSB-303	DMMJC4Q	Discontinued in Phase 1/2	Antibody	[106]
Onyvax-CR	DMRMRHO	Discontinued in Phase 1/2	NA	[107]
Avicine	DM82UR4	Discontinued in Phase 1	NA	[108]
ZD-0490	DM0Y8ZG	Discontinued in Phase 1	NA	[109]
CT-1746	DM84KOY	Terminated	NA	[111]
GW-278884	DMUG82P	Terminated	NA	[112]
IDD-5	DMDD3TB	Terminated	NA	[113]
Nacolomab tafenatox	DMCWBDH	Terminated	Monoclonal antibody	[114]
XR-3005	DMJLRC7	Terminated	NA	[115]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Drug(s)

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CCT251545	DMNA9KW	Preclinical	Small molecular drug	[110]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ASP4131	DM9B6WH	Investigative	NA	[7]
CA-50040	DMCLN6M	Investigative	NA	[116]
GSK-2136773	DMM1COB	Investigative	NA	[7]
IT-121	DMOFCM6	Investigative	NA	[7]
Ro-40-0655	DM8PYAN	Investigative	NA	[117]
SP-1062C-O	DM2EGD9	Investigative	NA	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 33 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PLA2G2A	TTO8QRU	No Known	Autosomal dominant	[118]
PTPRJ	TTWMKXP	No Known	Unknown	[119]
SRC	TT6PKBN	No Known	Unknown	[119]
BUB1	TT78309	Limited	Autosomal dominant	[120]
RTN4	TT7GXMU	Limited	Biomarker	[121]
MUTYH	TTNB0ZK	Disputed	Autosomal dominant	[120]
CHEK2	TT9ABMF	Moderate	Autosomal dominant	[122]
BMP4	TTD3BSX	Strong	Genetic Variation	[123]
CDH1	TTLAWO6	Strong	Genetic Variation	[124]
CDH3	TTARMD9	Strong	Genetic Variation	[123]
CUBN	TT9YLCR	Strong	Genetic Variation	[125]
CYP17A1	TTRA5BZ	Strong	Genetic Variation	[126]
EPHA5	TTV9KOD	Strong	Genetic Variation	[127]
ERAP1	TT60XFL	Strong	Genetic Variation	[125]
FADS2	TTT2VDU	Strong	Genetic Variation	[128]
FKBP5	TT0J5KQ	Strong	Genetic Variation	[123]
GATA3	TT45KOB	Strong	Genetic Variation	[129]
GREM1	TTOUZN5	Strong	Genetic Variation	[128]
KCNH1	TT9XKUC	Strong	Genetic Variation	[130]
LPAR1	TTQ6S1K	Strong	Genetic Variation	[123]
LRP1	TTF2V7I	Strong	Genetic Variation	[123]
NOTCH4	TTXDIK2	Strong	Genetic Variation	[131]
PIGU	TT2LHI6	Strong	Genetic Variation	[123]
SH2B3	TT36N7Z	Strong	Genetic Variation	[128]
SLC22A16	TTITAVR	Strong	Genetic Variation	[132]
SLC22A3	TTG2UMS	Strong	Genetic Variation	[133]
SLCO2A1	TTKVTQO	Strong	Genetic Variation	[131]
SMAD6	TTON5JB	Strong	Genetic Variation	[123]
SMAD7	TT0J32Z	Strong	Genetic Variation	[128]
SMAD9	TTX8EBV	Strong	Genetic Variation	[123]
TCF7L2	TT80QAL	Strong	Genetic Variation	[131]
TDP2	TTYF26D	Strong	Genetic Variation	[134]
TRPC6	TTRBT3W	Strong	Genetic Variation	[123]
------------------------------------------------------------------------------------


⏷ Show the Full List of 33 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC25A26	DT8HR5O	Strong	Genetic Variation	[123]
SLC6A18	DTGQ7FH	Strong	Genetic Variation	[123]
------------------------------------------------------------------------------------

This Disease Is Related to 105 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DCC	OT2C1SHW	No Known	Unknown	[119]
DLC1	OTP8LMCR	No Known	Unknown	[122]
PLA2G2A	OT1NY7BF	No Known	Autosomal dominant	[118]
PTPRJ	OT10OKOF	No Known	Unknown	[119]
SRC	OTETYX40	No Known	Unknown	[119]
BUB1	OT80DZMT	Limited	Autosomal dominant	[120]
FANCC	OTTIDM3P	Limited	Autosomal dominant	[122]
FLCN	OTVM78XM	Limited	Autosomal dominant	[122]
RTN1	OTCX1SMK	Limited	Biomarker	[121]
SETD6	OTH5APN1	Limited	Unknown	[119]
SPECC1	OTPEML48	Limited	Biomarker	[121]
MUTYH	OTXTKI7Q	Disputed	Autosomal dominant	[120]
CHEK2	OT8ZPCNS	Moderate	Autosomal dominant	[122]
ACOXL	OTW680HT	Strong	Genetic Variation	[129]
ACTR1B	OTGBCKLO	Strong	Genetic Variation	[124]
ACTRT3	OT2U08K8	Strong	Genetic Variation	[124]
ATF1	OT251CI0	Strong	Genetic Variation	[123]
BAALC	OTUZSRVF	Strong	Genetic Variation	[135]
BABAM1	OTCFPER6	Strong	Genetic Variation	[130]
BICC1	OTYRKIJ1	Strong	Genetic Variation	[126]
BMP5	OTC0Y6E0	Strong	Genetic Variation	[123]
BOC	OTXBCY9W	Strong	Genetic Variation	[123]
BTBD9	OTWQ6GA3	Strong	Genetic Variation	[136]
CABLES2	OTGD9A2A	Strong	Genetic Variation	[128]
CBLN2	OT29SSBE	Strong	Genetic Variation	[136]
CCND2	OTDULQF9	Strong	Genetic Variation	[128]
CFAP44	OT1273MD	Strong	Genetic Variation	[136]
CHD1	OT9R9G0H	Strong	Genetic Variation	[123]
CHRDL2	OTJU2I5H	Strong	Genetic Variation	[123]
CLEC3A	OTTOAEGT	Strong	Genetic Variation	[134]
COL4A2	OTJK1LKN	Strong	Genetic Variation	[123]
COLCA1	OT8BP6UD	Strong	Genetic Variation	[128]
CRTC3	OTVIGVUW	Strong	Genetic Variation	[124]
DCBLD1	OTA702JK	Strong	Genetic Variation	[137]
DENND5B	OTNDJJUR	Strong	Genetic Variation	[131]
DIP2B	OTP6KH82	Strong	Genetic Variation	[125]
DOCK3	OTF3YS2W	Strong	Genetic Variation	[136]
DRG1	OTIFYMI3	Strong	Genetic Variation	[136]
ECT2L	OTOSDMGV	Strong	Genetic Variation	[134]
EFCAB2	OTXEFI4O	Strong	Genetic Variation	[131]
EIF4ENIF1	OTZWDB2X	Strong	Genetic Variation	[136]
ELOVL5	OT375W1Z	Strong	Genetic Variation	[138]
ETV6	OTCZMG61	Strong	Genetic Variation	[139]
FAM193A	OTT0W53G	Strong	Genetic Variation	[136]
FEN1	OT6QGG7O	Strong	Genetic Variation	[124]
FMN1	OT9CID5R	Strong	Genetic Variation	[123]
FRY	OT74IAG2	Strong	Genetic Variation	[130]
GNG12	OTOGF42G	Strong	Genetic Variation	[136]
GPATCH1	OTQRDBY6	Strong	Genetic Variation	[140]
GPR143	OTWUA2AV	Strong	Genetic Variation	[141]
HERC2	OTNQYKOB	Strong	Genetic Variation	[136]
HHIP	OT77RQYS	Strong	Genetic Variation	[123]
HLA-F	OT76CM19	Strong	Genetic Variation	[136]
HNF1B	OTSYIC3T	Strong	Genetic Variation	[130]
HSPA12A	OTFOCDD6	Strong	Genetic Variation	[142]
KCNIP4	OTB1BS0X	Strong	Genetic Variation	[136]
KLF5	OT1ABI9N	Strong	Genetic Variation	[123]
KRT8	OTTM4X11	Strong	Genetic Variation	[130]
L1TD1	OTB2W20Y	Strong	Genetic Variation	[131]
LAMA5	OTIIXE4M	Strong	Genetic Variation	[123]
LAMC1	OTIG527N	Strong	Genetic Variation	[128]
LIMA1	OTONPC9R	Strong	Genetic Variation	[143]
LRIG1	OTY5HZN5	Strong	Genetic Variation	[128]
LSAMP	OTYXVQX2	Strong	Genetic Variation	[134]
MACF1	OTVIHD77	Strong	Genetic Variation	[144]
MAMSTR	OT4J6Z7G	Strong	Genetic Variation	[124]
MTX1	OTLSDNZO	Strong	Genetic Variation	[130]
MYNN	OT61R1HP	Strong	Genetic Variation	[145]
MYO16	OTMS3D8W	Strong	Genetic Variation	[136]
MYRF	OTKF6AEB	Strong	Genetic Variation	[131]
MZF1	OTMVZCPW	Strong	Genetic Variation	[123]
NEK10	OTN0JAYL	Strong	Genetic Variation	[130]
NXN	OT35N40G	Strong	Genetic Variation	[123]
OR1J2	OTIQTQHU	Strong	Genetic Variation	[136]
PCNX1	OTFP8XHC	Strong	Genetic Variation	[144]
PLCH1	OT6Z1L2E	Strong	Genetic Variation	[146]
PLEKHG6	OTZWA27A	Strong	Genetic Variation	[123]
PNKD	OT6G9UXN	Strong	Genetic Variation	[128]
POLD3	OTEQEFQ2	Strong	Genetic Variation	[128]
POU5F1B	OT0FKQ51	Strong	Genetic Variation	[128]
PPP1R21	OTWN6N7T	Strong	Genetic Variation	[131]
PREX1	OTUTPVA9	Strong	Genetic Variation	[131]
RAD51B	OTCJVRMY	Strong	Genetic Variation	[130]
RALY	OT78NNWY	Strong	Genetic Variation	[130]
RETREG3	OTEUQ2MI	Strong	Genetic Variation	[134]
RHPN2	OTTYWMF6	Strong	Genetic Variation	[128]
RIPOR3	OTHZ4RKK	Strong	Genetic Variation	[123]
RNF4	OTCMXQRE	Strong	Genetic Variation	[136]
RNGTT	OT59E0KX	Strong	Genetic Variation	[134]
RTEL1	OTI3PJCT	Strong	Genetic Variation	[123]
SBF2	OTBB8NO8	Strong	Genetic Variation	[124]
SCAF8	OTSCFMK3	Strong	Genetic Variation	[134]
SHROOM2	OTZ2FJ7Q	Strong	Genetic Variation	[124]
SPSB2	OT7ZVT8R	Strong	Genetic Variation	[126]
SYMPK	OTYAUDXV	Strong	Genetic Variation	[140]
TANC1	OTF6TZ8E	Strong	Genetic Variation	[123]
TBX3	OTM64N7K	Strong	Genetic Variation	[147]
TET2	OTKKT03T	Strong	Genetic Variation	[123]
TFEB	OTJUJJQY	Strong	Genetic Variation	[124]
TMBIM1	OTE47B57	Strong	Genetic Variation	[128]
TMEM258	OTXSDU14	Strong	Genetic Variation	[131]
TMTC1	OTZ7NW96	Strong	Genetic Variation	[134]
TNS3	OTPG2D8Z	Strong	Genetic Variation	[124]
TOX2	OT7RZRVK	Strong	Genetic Variation	[123]
TTC22	OTFNNLI1	Strong	Genetic Variation	[123]
------------------------------------------------------------------------------------


⏷ Show the Full List of 105 DOT(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799).
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6882).
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
7	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
8	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217564
9	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
10	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5702).
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8090).
14	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
15	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6883).
16	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17	ClinicalTrials.gov (NCT00761280) Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma. U.S. National Institutes of Health.
18	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT00043212) Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.. U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT00085826) A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
22	ClinicalTrials.gov (NCT02077868) Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment. U.S. National Institutes of Health.
23	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027311)
24	ClinicalTrials.gov (NCT00465491) Study of Picoplatin Efficacy After Relapse. U.S. National Institutes of Health.
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018787)
26	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009783)
27	ClinicalTrials.gov (NCT01955837) Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT05378867) A Phase 3, Multicenter, Randomized and Double-blind Study Assessing the Interchangeability Between TRS003 and China-approved Bevacizumab? (Also Called China-approved Avastin) For First-Line Treatment of Patients With Metastatic Colorectal Cancer (CRC). U.S.National Institutes of Health.
29	ClinicalTrials.gov (NCT02138422) A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer. U.S. National Institutes of Health.
30	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
31	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024430)
32	Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40.
33	Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003 Jul 1;21(13):2508-18.
34	ClinicalTrials.gov (NCT04486378) A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection. U.S.National Institutes of Health.
35	ClinicalTrials.gov (NCT00003125) Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT01327612) Open Label Extension Study of Conatumumab and AMG 479. U.S. National Institutes of Health.
37	ClinicalTrials.gov (NCT01353222) DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma. U.S. National Institutes of Health.
38	ClinicalTrials.gov (NCT00309179) A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors. U.S. National Institutes of Health.
39	ClinicalTrials.gov (NCT00655161) A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation. U.S. National Institutes of Health.
40	ClinicalTrials.gov (NCT01769196) A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
41	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7902).
42	Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
43	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4987).
44	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026493)
45	Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol.2005 Sep 20;23(27):6763-70.
46	Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer. 2013 Dec 15;119(24):4223-30.
47	ClinicalTrials.gov (NCT01577173) A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
48	ClinicalTrials.gov (NCT01574716) Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation. (SOURCE). U.S. National Institutes of Health.
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7872).
50	ClinicalTrials.gov (NCT00773097) Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma. U.S. National Institutes of Health.
51	ClinicalTrials.gov (NCT02455596) Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors.
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031614)
53	Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380-8.
54	ClinicalTrials.gov (NCT00003802) Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma. U.S. National Institutes of Health.
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037469)
56	Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011 Jan-Feb; 2(1): 73-79.
57	ClinicalTrials.gov (NCT02141295) A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer
58	A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother. 1999 Nov;22(6):481-8.
59	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8412).
60	ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
61	ClinicalTrials.gov (NCT04479436) A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer. U.S. National Institutes of Health.
62	A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer. 2008 Sep 2;99(5):722-6.
63	Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80.
64	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
65	ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
66	ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor
67	ClinicalTrials.gov (NCT04046445) Phase 1b Study to Evaluate ATP128, With or Without BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01). U.S. National Institutes of Health.
68	ClinicalTrials.gov (NCT00529984) A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies. U.S. National Institutes of Health.
69	ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
70	ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
71	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029192)
72	Clinical pipeline report, company report or official report of ISA Pharmaceuticals BV.
73	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
74	ClinicalTrials.gov (NCT03531632) MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer. U.S. National Institutes of Health.
75	ClinicalTrials.gov (NCT04616196) Study of NKTR 255 in Combination With Cetuximab in Solid Tumors. U.S. National Institutes of Health.
76	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006889)
77	ClinicalTrials.gov (NCT01227772) Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer. U.S. National Institutes of Health.
78	ClinicalTrials.gov (NCT04495621) MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01). U.S. National Institutes of Health.
79	ClinicalTrials.gov (NCT03391232) PolyPEPI1018 Vaccine and CDx for the Treatment of Metastatic Colorectal Cancer (OBERTO) (OBERTO). U.S. National Institutes of Health.
80	ClinicalTrials.gov (NCT03265080) Expressing Personalized Tumor Antigens Study (NEO). U.S. National Institutes of Health.
81	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026463)
82	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
83	ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
84	ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
85	ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
86	Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353-63.
87	ClinicalTrials.gov (NCT05387265) A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101). U.S.National Institutes of Health.
88	ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
89	Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cells proliferation. Am J Cancer Res. 2011; 1(3): 356-361.
90	ClinicalTrials.gov (NCT02148328) Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.
91	ClinicalTrials.gov (NCT00199797) Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
92	ClinicalTrials.gov (NCT05014360) A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis. U.S.National Institutes of Health.
93	ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
94	ClinicalTrials.gov (NCT00291486) Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
95	Clinical pipeline report, company report or official report of Roche.
96	Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with ... Cancer Immunol Immunother. 2007 May;56(5):689-98.
97	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022136)
98	Clinical pipeline report, company report or official report of Immunomedics.
99	Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
100	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024385)
101	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002538)
102	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013809)
103	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030998)
104	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006762)
105	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027277)
106	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009269)
107	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016872)
108	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009467)
109	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004134)
110	Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377.
111	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006498)
112	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011272)
113	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019402)
114	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007713)
115	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005580)
116	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849).
117	Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8.
118	Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP. Hum Genet. 1997 Sep;100(3-4):345-9. doi: 10.1007/s004390050514.
119	The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
120	Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
121	Meat, starch and non-starch polysaccharides, are epidemiological and experimental findings consistent with acquired genetic alterations in sporadic colorectal cancer?.Cancer Lett. 1997 Mar 19;114(1-2):25-34. doi: 10.1016/s0304-3835(97)04618-1.
122	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
123	Discovery of common and rare genetic risk variants for colorectal cancer.Nat Genet. 2019 Jan;51(1):76-87. doi: 10.1038/s41588-018-0286-6. Epub 2018 Dec 3.
124	Association analyses identify 31 new risk loci for colorectal cancer susceptibility.Nat Commun. 2019 May 14;10(1):2154. doi: 10.1038/s41467-019-09775-w.
125	A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.Sci Rep. 2015 May 20;5:10442. doi: 10.1038/srep10442.
126	Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk.Gastroenterology. 2016 Jun;150(7):1633-1645. doi: 10.1053/j.gastro.2016.02.076. Epub 2016 Mar 8.
127	Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.PLoS One. 2018 Dec 17;13(12):e0208080. doi: 10.1371/journal.pone.0208080. eCollection 2018.
128	Novel Common Genetic Susceptibility Loci for Colorectal Cancer.J Natl Cancer Inst. 2019 Feb 1;111(2):146-157. doi: 10.1093/jnci/djy099.
129	Genome-wide diet-gene interaction analyses for risk of colorectal cancer.PLoS Genet. 2014 Apr 17;10(4):e1004228. doi: 10.1371/journal.pgen.1004228. eCollection 2014 Apr.
130	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
131	Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.Gastroenterology. 2019 Apr;156(5):1455-1466. doi: 10.1053/j.gastro.2018.11.066. Epub 2018 Dec 6.
132	Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses.Biomark Res. 2018 Jun 13;6:17. doi: 10.1186/s40364-018-0133-z. eCollection 2018.
133	Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population.Gut. 2011 Jun;60(6):799-805. doi: 10.1136/gut.2010.215947. Epub 2011 Jan 17.
134	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.Sci Rep. 2015 Dec 1;5:17369. doi: 10.1038/srep17369.
135	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies.PLoS One. 2018 Apr 26;13(4):e0196245. doi: 10.1371/journal.pone.0196245. eCollection 2018.
136	Bayesian and frequentist analysis of an Austrian genome-wide association study of colorectal cancer and advanced adenomas.Oncotarget. 2017 Oct 9;8(58):98623-98634. doi: 10.18632/oncotarget.21697. eCollection 2017 Nov 17.
137	Genome-wide association study of colorectal cancer identifies six new susceptibility loci.Nat Commun. 2015 Jul 7;6:7138. doi: 10.1038/ncomms8138.
138	Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.Carcinogenesis. 2016 Jan;37(1):87-95. doi: 10.1093/carcin/bgv161. Epub 2015 Nov 19.
139	Common genetic variation in ETV6 is associated with colorectal cancer susceptibility.Nat Commun. 2016 May 5;7:11478. doi: 10.1038/ncomms11478.
140	Novel colon cancer susceptibility variants identified from a genome-wide association study in African Americans.Int J Cancer. 2017 Jun 15;140(12):2728-2733. doi: 10.1002/ijc.30687. Epub 2017 Mar 28.
141	Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.Nat Genet. 2012 May 27;44(7):770-6. doi: 10.1038/ng.2293.
142	Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer.Nat Genet. 2013 Feb;45(2):191-6. doi: 10.1038/ng.2505. Epub 2012 Dec 23.
143	Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis.Hum Mol Genet. 2014 Sep 1;23(17):4729-37. doi: 10.1093/hmg/ddu177. Epub 2014 Apr 15.
144	Genome-wide association study of colorectal cancer in Hispanics.Carcinogenesis. 2016 Jun;37(6):547-556. doi: 10.1093/carcin/bgw046. Epub 2016 Apr 18.
145	Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33.Nat Genet. 2010 Nov;42(11):973-7. doi: 10.1038/ng.670. Epub 2010 Oct 24.
146	GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12.Carcinogenesis. 2018 May 3;39(5):652-660. doi: 10.1093/carcin/bgy026.
147	Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis.Gastroenterology. 2013 Apr;144(4):799-807.e24. doi: 10.1053/j.gastro.2012.12.020. Epub 2012 Dec 22.